Remove Antibody Remove FDA Approval Remove Genotype
article thumbnail

Top 30 New Medical Devices of 2024

XTalks

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Date of FDA approval : March 29, 2024 Approved for : To detect exposure to human parvovirus B19. TriClip size comparison photo. Photo courtesy of Abbott Medical.

article thumbnail

New HCV Test Enables Diagnosis and Treatment in a Single Visit

XTalks

“This simple-to-use test detects the full range of known HCV genotypes in about an hour and can be performed on a small volume of blood collected via fingerstick,” said Dr. David H. Persing, Cepheid’s chief medical and scientific officer in Cepheid’s press release. billion in 2018 and is projected to reach $9.84

RNA 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. FOSTER CITY, Calif.–(BUSINESS –(BUSINESS WIRE)– Gilead Sciences, Inc. About Trodelvy.

article thumbnail

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

Prior to the FDA approval of Trodelvy, patients with previously treated metastatic TNBC had few treatment options in this high unmet-need setting. The FDA granted accelerated approval to Trodelvy in April 2020 based on objective response rate and duration of response results in a Phase 1/2 study. About Trodelvy.

HR 52